Free Trial

Mereo BioPharma Group (MREO) Earnings Date, Estimates & Call Transcripts

Mereo BioPharma Group logo
$3.35 +0.06 (+1.82%)
(As of 12/20/2024 05:16 PM ET)
Get Mereo BioPharma Group Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

MREO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MREO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Mereo BioPharma Group Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20241-$0.01-$0.01-$0.01
Q3 20241-$0.01-$0.01-$0.01
Q4 20241$0.10$0.10$0.10
20243$0.08$0.08$0.08
Q1 20251$0.00$0.00$0.00
Q2 20251$0.04$0.04$0.04
Q3 20251-$0.01-$0.01-$0.01
Q4 20251-$0.02-$0.02-$0.02
FY 20254$0.01$0.01$0.01

Mereo BioPharma Group Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/15/2024Q1 2024--$0.01 -$0.01-$0.01--
9/7/2023Q2 2023-$0.02-$0.02----

Mereo BioPharma Group Earnings - Frequently Asked Questions

Mereo BioPharma Group (NASDAQ:MREO) has a recorded annual revenue of $1 million.

Mereo BioPharma Group (NASDAQ:MREO) has a recorded net income of -$29.47 million. MREO has generated $0.00 earnings per share over the last four quarters.

More Earnings Resources from MarketBeat



This page (NASDAQ:MREO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners